+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunoglobulin Product Market by Product Type, Source, Route of Administration, Application - Global Forecast 2026-2032- Product Image
Immunoglobulin Product Market by Product Type, Source, Route of Administration, Application - Global Forecast 2026-2032- Product Image
Sale

Immunoglobulin Product Market by Product Type, Source, Route of Administration, Application - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904902
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immunoglobulin Product Market is projected to reach USD 24.00 Billion in 2026. It is expected to continue growing at a CAGR of 13.04%, reaching USD 50.29 Billion by 2032.

Immunoglobulin products are plasma-derived biologic therapies used to replace or modulate antibodies in patients with immune-mediated and infection-risk conditions. The category includes intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and specialty formulations used across primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, immune thrombocytopenia, multifocal motor neuropathy, Kawasaki disease, multifocal motor neuropathy, and selected secondary immunodeficiency settings.

The immunoglobulin product market is shaped by rising diagnosis of immune disorders, broader use in neurology and hematology, and persistent supply constraints tied to human plasma collection, fractionation capacity, viral safety testing, regulatory release, and cold-chain distribution. For industry leaders, competitive advantage depends on secure plasma access, reliable manufacturing quality, patient-friendly administration options, traceability, and payer-supported evidence of clinical value.

Transformative Shifts in the Immunoglobulin Landscape

The immunoglobulin product landscape is moving from hospital-centered IVIG administration toward more flexible care models that include home infusion and SCIG self-administration. This shift is supported by clinical practice patterns that favor reduced infusion-center burden, stable serum IgG exposure, fewer systemic infusion-related reactions for some patients, and improved patient autonomy where medically appropriate.

At the same time, supply resilience has become a strategic priority. Because immunoglobulin products depend on donated human plasma and complex fractionation, short-term demand shocks cannot be solved instantly. Manufacturers and healthcare systems are investing in donor-center networks, yield optimization, manufacturing redundancy, validated quality systems, improved inventory planning, and appropriate-use protocols to protect continuity of therapy for patients who rely on these essential biologics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the full immunoglobulin product value chain. In plasma operations, AI-enabled analytics can improve donor scheduling, forecast collection volumes, identify operational bottlenecks, support compliance monitoring, and strengthen traceability across regulated donation networks.

In manufacturing and commercial operations, machine learning can support batch-trend analysis, deviation detection, demand forecasting, pharmacovigilance signal management, inventory allocation, and cold-chain risk prediction. The cumulative impact is not replacement of regulatory science or clinician judgment, but faster and more consistent decision support in a market where product availability, safety, traceability, and appropriate allocation are critical.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America remains a central hub for immunoglobulin product demand and plasma supply, led by the United States with extensive plasma collection infrastructure, advanced specialty care, and strong utilization in immunology, neurology, and hematology. Canada has a more centralized blood and plasma governance model, making supply planning, national coordination, domestic collection strategy, and import dependence important policy considerations.

Europe is defined by mature regulatory oversight, broad clinical adoption, national reimbursement systems, and continuing policy focus on plasma self-sufficiency and appropriate use of IVIG and SCIG. Asia-Pacific is expanding as diagnosis rates improve in China, India, Japan, South Korea, and Australia, although access varies by reimbursement maturity, local fractionation capacity, specialist availability, regulatory pathways, and urban-rural healthcare differences.

Latin America shows growing demand in Brazil and Mexico, but availability can be uneven because of budget constraints, tender cycles, distribution complexity, and reliance on imported plasma derivatives. The Middle East, especially GCC markets, benefits from investment in tertiary care and specialty hospitals, while Africa faces the largest access gaps due to limited plasma infrastructure, affordability barriers, constrained diagnostic capacity, and uneven cold-chain reach.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are gaining relevance as immunology and neurology services expand, but product access differs sharply between higher-income health systems and markets with limited reimbursement, specialist coverage, and plasma-derived therapy budgets. The GCC is characterized by strong hospital investment, demand for advanced biologics, and centralized procurement that can accelerate access when supply contracts, registration pathways, and logistics capacity are secure.

The European Union remains a major regulatory and demand center, with strict quality standards, pharmacovigilance requirements, national reimbursement assessment, and policy focus on plasma sufficiency. BRICS countries represent a strategically important opportunity because of large populations, rising diagnosis, and investments in domestic biomanufacturing and healthcare capacity, although pricing, reimbursement, import reliance, and access barriers remain significant.

G7 markets account for substantial global immunoglobulin consumption because they combine advanced diagnostics, established clinical guidelines, broad specialist networks, and payer coverage for approved indications. NATO countries overlap substantially with high-income systems in North America and Europe, where supply security, strategic reserves, cross-border logistics, and resilient healthcare infrastructure are increasingly important for plasma-derived medicinal products.

Key Country Insights: U.S., Canada, Mexico, Brazil, Europe, China, India, Japan, Australia & South Korea

The United States is the most influential immunoglobulin product market because of its large diagnosed patient base, strong specialty infusion ecosystem, broad payer channels, and unmatched plasma collection scale. Canada emphasizes managed access and national blood-system coordination, while Mexico is expanding specialty care but remains sensitive to pricing, reimbursement gaps, product registration, and public procurement dynamics.

Brazil leads Latin American demand, supported by a large healthcare system and growing biologics use, while the United Kingdom, Germany, France, Italy, and Spain represent established European markets with guideline-driven utilization, pharmacovigilance expectations, and payer scrutiny. Russia has demand for plasma-derived therapies but faces supply-chain, currency, procurement, and geopolitical constraints that can affect access and continuity.

China and India offer long-term growth potential as diagnosis improves, hospital capacity expands, and healthcare coverage broadens, but access remains uneven across regions and income segments. Japan, Australia, and South Korea are mature Asia-Pacific markets with high regulatory standards, strong specialty care, established blood-system oversight, and increasing emphasis on patient-centered administration models such as SCIG and home-based care where clinically suitable.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize plasma supply security by diversifying donor-center networks, strengthening long-term collection partnerships, improving donor retention, and investing in fractionation capacity and manufacturing redundancy. In a constrained market, continuity of supply is both a core commercial differentiator and a patient-safety obligation.

Organizations should also expand evidence generation for approved indications, real-world outcomes, safety monitoring, dosing patterns, switching practices, and health-economic value. Patient support programs, home-infusion partnerships, SCIG education, digital adherence tools, and clinician-facing appropriate-use resources can improve persistence while supporting payers that require proof of responsible utilization.

To improve resilience, leaders should integrate AI-enabled demand planning, cold-chain visibility, pharmacovigilance analytics, and quality-management systems without compromising regulatory oversight. Regional strategies should align product availability with reimbursement rules, tender cycles, clinical guideline adoption, and the documented needs of immunology, neurology, and hematology specialists.

Research Methodology

This executive summary is structured using a secondary research methodology grounded in publicly available regulatory, clinical, and industry intelligence sources. Relevant inputs include prescribing information, regulatory guidance from agencies such as the FDA and EMA, clinical guidelines, blood and plasma policy publications, healthcare access reports, pharmacovigilance references, and peer-reviewed literature on immunoglobulin use.

Insights were synthesized through comparative regional analysis, product-category assessment, demand-driver evaluation, supply-chain review, and healthcare access interpretation. The methodology emphasizes verified industry facts, avoids unsupported projections, and focuses on commercially actionable themes affecting immunoglobulin product access, manufacturing, reimbursement, quality assurance, and adoption.

Conclusion

Immunoglobulin products will remain essential therapies in immunology, neurology, hematology, and inflammatory disease management. Demand is supported by better diagnosis, established clinical indications, expanding care pathways, and patient preference for flexible administration, while supply remains limited by the realities of plasma collection, fractionation timelines, quality testing, and biologics manufacturing.

Market leaders that combine secure plasma sourcing, disciplined quality systems, AI-enabled operations, patient-centered commercialization, and robust evidence generation will be best positioned to compete. The future of the immunoglobulin product market will be defined by reliability, clinical evidence, equitable access, and resilient global supply chains.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immunoglobulin Product Market, by Product Type
7.1. Hyperimmune Globulin
7.2. Standard Immunoglobulin
8. Immunoglobulin Product Market, by Source
8.1. Pooled Human Plasma
8.2. Recombinant
9. Immunoglobulin Product Market, by Route Of Administration
9.1. Intramuscular
9.2. Intravenous
9.3. Subcutaneous
10. Immunoglobulin Product Market, by Application
10.1. Hematological Disorders
10.1.1. Hemolytic Anemia
10.1.2. Idiopathic Thrombocytopenic Purpura
10.2. Infectious Diseases
10.2.1. Hepatitis A
10.2.2. Rubella
10.2.3. Varicella
10.3. Neurological Disorders
10.3.1. Chronic Inflammatory Demyelinating Polyneuropathy
10.3.2. Guillain-Barre Syndrome
10.3.3. Myasthenia Gravis
10.4. Primary Immune Deficiency
10.4.1. Common Variable Immunodeficiency
10.4.2. Severe Combined Immunodeficiency
10.4.3. X-Linked Agammaglobulinemia
11. Asia-Pacific Immunoglobulin Product Market
12. North America Immunoglobulin Product Market
13. Latin America Immunoglobulin Product Market
14. Europe Immunoglobulin Product Market
15. Middle East Immunoglobulin Product Market
16. Africa Immunoglobulin Product Market
17. ASEAN Immunoglobulin Product Market
18. GCC Immunoglobulin Product Market
19. European Union Immunoglobulin Product Market
20. BRICS Immunoglobulin Product Market
21. G7 Immunoglobulin Product Market
22. NATO Immunoglobulin Product Market
23. United States Immunoglobulin Product Market
24. Canada Immunoglobulin Product Market
25. Mexico Immunoglobulin Product Market
26. Brazil Immunoglobulin Product Market
27. United Kingdom Immunoglobulin Product Market
28. Germany Immunoglobulin Product Market
29. France Immunoglobulin Product Market
30. Russia Immunoglobulin Product Market
31. Italy Immunoglobulin Product Market
32. Spain Immunoglobulin Product Market
33. China Immunoglobulin Product Market
34. India Immunoglobulin Product Market
35. Japan Immunoglobulin Product Market
36. Australia Immunoglobulin Product Market
37. South Korea Immunoglobulin Product Market
38. Competitive Landscape
38.1. Market Concentration Analysis, 2025
38.1.1. Concentration Ratio (CR)
38.1.2. Herfindahl Hirschman Index (HHI)
38.2. Recent Developments & Impact Analysis, 2025
38.3. Product Portfolio Analysis, 2025
38.4. Benchmarking Analysis, 2025
39. Company Profiles
39.1. ADMA Biologics, Inc.
39.2. Bharat Serums and Vaccines Limited
39.3. Bio Products Laboratory Limited
39.4. Biotest AG
39.5. China Biologic Products Holdings, Inc.
39.6. CSL Limited
39.7. Emergent BioSolutions Inc.
39.8. GC Biopharma Corp.
39.9. Green Cross Corporation
39.10. Grifols, S.A.
39.11. Hualan Biological Engineering Inc.
39.12. Intas Pharmaceuticals Ltd.
39.13. Kamada Ltd.
39.14. Kedrion S.p.A.
39.15. LFB S.A.
39.16. Octapharma AG
39.17. PharmaSwiss SA
39.18. Prothya Biosolutions B.V.
39.19. Reliance Life Sciences Pvt. Ltd.
39.20. Sanquin Plasma Products B.V.
39.21. Shanghai RAAS Blood Products Co., Ltd.
39.22. SK Plasma Co., Ltd.
39.23. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 35. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 47. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 48. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL STANDARD IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL STANDARD IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL STANDARD IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL POOLED HUMAN PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL POOLED HUMAN PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL POOLED HUMAN PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL HEMOLYTIC ANEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HEMOLYTIC ANEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HEMOLYTIC ANEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HEPATITIS A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HEPATITIS A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HEPATITIS A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL RUBELLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RUBELLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL RUBELLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL VARICELLA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL VARICELLA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL VARICELLA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MYASTHENIA GRAVIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MYASTHENIA GRAVIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MYASTHENIA GRAVIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PRIMARY IMMUNE DEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PRIMARY IMMUNE DEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PRIMARY IMMUNE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL COMMON VARIABLE IMMUNODEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL COMMON VARIABLE IMMUNODEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL COMMON VARIABLE IMMUNODEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL SEVERE COMBINED IMMUNODEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL SEVERE COMBINED IMMUNODEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SEVERE COMBINED IMMUNODEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL X-LINKED AGAMMAGLOBULINEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL X-LINKED AGAMMAGLOBULINEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL X-LINKED AGAMMAGLOBULINEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 105. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 108. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 110. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 111. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 112. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 123. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 125. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 126. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 128. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 129. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 130. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 131. AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 132. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 134. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 135. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 137. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 138. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 139. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 140. ASEAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 141. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 143. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 144. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 146. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 147. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 148. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 149. GCC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 159. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 160. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 161. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 162. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 164. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 165. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 166. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 167. BRICS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 168. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 169. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 170. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 171. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 174. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 175. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 176. G7 IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 177. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 178. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 179. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 180. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 182. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 183. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 184. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 185. NATO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 186. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 187. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 189. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 191. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 192. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 195. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 197. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 198. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 200. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 201. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 202. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 203. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 204. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 205. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 206. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 207. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 209. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 210. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 211. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 212. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 213. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 214. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 215. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 216. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 218. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 219. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 220. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 221. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 222. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 223. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 224. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 225. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 226. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 227. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 230. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 231. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 232. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 233. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 234. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 235. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 236. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 237. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 238. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 239. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 240. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 241. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 242. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 243. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 244. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 245. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 246. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 247. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 248. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 249. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 250. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 251. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 252. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 253. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 254. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 255. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 256. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 257. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 258. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 259. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 260. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 261. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 262. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 263. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 264. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 265. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 266. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 267. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 268. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 269. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 270. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 271. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 272. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 273. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 274. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 275. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 276. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 277. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 278. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 279. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 280. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 281. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 282. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 283. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 284. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 285. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 286. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 287. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 288. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 289. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 290. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 291. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 292. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 293. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 294. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 295. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 296. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 297. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 298. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 299. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 300. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 301. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 302. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 303. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 304. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 305. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 306. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 307. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 308. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 309. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 310. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 311. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)
TABLE 312. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 313. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 314. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
TABLE 315. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 316. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 317. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 318. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 319. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 320. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Immunoglobulin Product market report include:
  • ADMA Biologics, Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Limited
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GC Biopharma Corp.
  • Green Cross Corporation
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion S.p.A.
  • LFB S.A.
  • Octapharma AG
  • PharmaSwiss SA
  • Prothya Biosolutions B.V.
  • Reliance Life Sciences Pvt. Ltd.
  • Sanquin Plasma Products B.V.
  • Shanghai RAAS Blood Products Co., Ltd.
  • SK Plasma Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages182
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 24 Billion
Forecasted Market Value ( USD ) by 2032 $ 50.29 Billion
Compound Annual Growth Rate13.0%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Intravenous Immunoglobulin Market - Global Forecast 2026-2032 - Product Image

Intravenous Immunoglobulin Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Subcutaneous Immunoglobulin Market - Global Forecast 2026-2032 - Product Image

Subcutaneous Immunoglobulin Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Subcutaneous Immunoglobulin - Global Strategic Business Report - Product Image

Subcutaneous Immunoglobulin - Global Strategic Business Report

  • Report
  • 226 Pages
  • Global
From
Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2026-2034 - Product Image

Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2026-2034

  • Report
  • 136 Pages
  • Global
From

About the Immunoglobulin Market

The Immunoglobulin market is a segment of the Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. Immunoglobulin (Ig) is a type of protein found in the blood that helps fight infection and disease. It is used to treat a variety of immune-related conditions, including autoimmune diseases, allergies, and infections. Immunoglobulin therapies are typically administered intravenously or subcutaneously, and can be used to replace or supplement the body's natural Ig production. The Immunoglobulin market is highly competitive, with a number of companies offering a range of products. These products vary in terms of dosage, delivery method, and cost. Companies in the market are focused on developing new therapies and improving existing ones, as well as expanding their product portfolios. Some of the major companies in the Immunoglobulin market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.